SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject9/25/2000 5:04:15 PM
From: IRWIN JAMES FRANKEL   of 508
 
From Yahoo on Barrons

Barron's
by: ariad_pharma 9/25/00 6:14 am
Msg: 79 of 79

Antony Milford (Munder Framlington Healthcare)
...
One such company is InterMune Pharmaceuticals, a biotech outfit whose key product, Actimmune, was approved for a very rare immune disorder called graulomatous disease, which promised only a $10 million worldwide market. But clinical data showed that the drug fights a lung disease called idiopathic pulmonary fibrosis -- potentially a $500 million market. Actimmune is now being used as a treatment for pulmonary fibrosis, even though it hasn't been formally approved for this. InterMune is seeking such approval. But sales of Actimmune are already rising. In the second quarter, they came to $3 million, versus $1 million in the comparable 1999 period.

In addition to its unexpected upside, Milford likes the fact that InterMune owns 100% of the product and is marketing it by itself, a rarity for a small biotech firm. The company, Milford predicts, will book its first profits next year.
...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News